---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-033861"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2026-05-12T11:05:23+00:00"
generated_at: "2026-05-12T11:13:26.176983+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Q1 2026 net loss $25.1M; cash $268.3M; new Roche DAC collaboration

## Summary
- Revenue $6.2M (down from $7.2M YoY); net loss $25.1M ($0.20 EPS) vs $26.3M ($0.37 EPS).
- Cash $268.3M at March 31, 2026; runway to end of 2028.
- Decision to not advance CFT8919 (EGFR L858R degrader) outside Greater China.
- New collaboration with Roche for degrader-antibody conjugates; $20M upfront payment received.
- Cemsidomide Phase 2 MOMENTUM trial enrollment on track; Phase 1b with elranatamab first patient dosed.

## SEC filing metadata
- accession: 0001628280-26-033861
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2026-05-12T11:05:23+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/0001628280-26-033861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/cccc-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-033861
- JSON: https://secwatch.observer/filing/0001628280-26-033861.json
- Plain text: https://secwatch.observer/filing/0001628280-26-033861.txt

## Key facts
- Earnings Releases
  C4 Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $6.2 million, net income $25.1 million.
  - Period: first quarter ended March 31, 2026
  - Revenue: $6.2 million
  - Net income: $25.1 million
  - Result: reported results
  source text: Global Healthcare Conference taking place in Miami, FL from June 8 - 10, 2026. FIRST QUARTER 2026 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2026 was $6.2 million, compared to $7.2 million for the first quarter of 2025. The decrease in revenue resulted from the conclusion of the research collaboration with Merck and the prioritization of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/0001628280-26-033861-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.